Topic:

M&A

Latest Headlines

Latest Headlines

Siemens sells hearing aid biz for $2.7B amid rumors it will exit healthcare entirely

In another sign Siemens is pivoting away from healthcare and towards the energy industry, the German conglomerate announced the sale of its hearing aid business for $2.69 billion to private equity firm EQT Partners and Santo Holding, the investment company of Germany's Strüngmann family.

Actavis bid looms as Allergan says it's been approached (again) on merger

Allergan today confirmed what much of the industry has been buzzing about for some time now: It's in takeover discussions with another company other than the acquisition-hungry Valeant. And the business news outlets quickly identified Actavis as the interested party.

UPDATED: Perrigo snaps up OTC specialist Omega in deal worth $4.5B

Perennial dealmaker Perrigo signed on the dotted line for Belgium's Omega Pharma, elbowing past rival bidders to expand its footprint in the global OTC market.  

Allergan loses fight to block Ackman from voting for a Valeant takeover

Valeant and partner Bill Ackman have dodged a serious roadblock in their quest to acquire Allergan. A 9.7% roadblock, if you will.

Allergan discloses a secret admirer looking to make an offer. Could it be... Actavis?

Amid a heated takeover fight with Valeant, Allergan says it's got a mystery suitor. But according to The Wall Street Journal 's sources, it's not all that mysterious.

AstraZeneca builds cancer R&D dream house with $150M Definiens buyout, J&J deal

Looking to build an oncology powerhouse, AstraZeneca has scooped up the diagnostics player Definiens with a down payment of $150 million while executing another drug development partnership with J&J and Pharmacyclics to add to its growing portfolio of immuno-oncology deals

Covidien sells drug-coated balloon for $30M to appease regulators as it barrels toward Medtronic merger

Another hurdle toward the long-anticipated closure of Covidien's $43 billion merger with Medtronic was crossed today. Covidien announced that it is selling its clinical-stage Stellarex drug-coated angioplasty balloon for peripheral artery disease to Spectranetics for $30 million.

LabCorp is buying Covance for $5.6B to cut in on the CRO boom

Diagnostics giant LabCorp is buying its way into the upper ranks of the CRO business, signing a deal to pay $5.6 billion for Covance and create an end-to-end testing conglomerate.

IDEXX follows positive earnings with acquisition of Animana

Shares of IDEXX Laboratories rose nearly 5% to $141.67 last week after reporting third-quarter net income that handily beat analyst estimates and announcing the acquisition of Netherlands-based Animana, which makes software for veterinary practices.

Timely deals boost Charles River's balance sheet

A string of acquisitions has revenue rolling at Charles River Laboratories, and the CRO has inked another M&A deal it hopes will pay off with a larger market share.